MedTrace Logo

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-03-10

No results posted yet for this study

Summary

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Conditions

  • Hypertension (HTN)
  • Cardiometabolic Diseases

Interventions

DIETARY_SUPPLEMENT

High Salt Diet

8 days of diet with high salt content will be given to the study participants

DIETARY_SUPPLEMENT

Low Salt Diet

8 days of diet with low salt content will be given to the study participants

DIETARY_SUPPLEMENT

Saline Infusion

2 Liters of normal saline infusion (0.25 ml/kg/min over 2 hours) will be given to the study participants at the end of each study period

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Pankaj Arora, MD, FAHA · University of Alabama at Birmingham

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2030-06-01
Completion
2030-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118592 on ClinicalTrials.gov